Subtopic Deep Dive

Mitragynine Pharmacology and Receptor Interactions
Research Guide

What is Mitragynine Pharmacology and Receptor Interactions?

Mitragynine pharmacology examines the binding affinities, biased agonism, and signaling pathways of mitragynine at mu-opioid and adrenergic receptors from Mitragyna speciosa.

Mitragynine acts as a partial agonist at mu-opioid receptors with reduced respiratory depression compared to traditional opioids. Studies detail its structure-activity relationships and downstream G-protein signaling. Over 40 papers, including foundational works by Takayama (2004, 344 citations) and Kruegel et al. (2016, 296 citations), map these interactions.

Curated Papers

Key Challenges

Why It Matters

Mitragynine offers a scaffold for non-respiratory-depressant analgesics, addressing opioid crisis limitations (Kruegel et al., 2016). Its biased agonism at mu-opioid receptors minimizes side effects while retaining pain relief, as shown in pseudoindoxyl derivatives (Váradi et al., 2016). Clinical translation supports kratom-based withdrawal treatments (Boyer et al., 2008) and novel opioid modulator development (Takayama et al., 2002).

Key Research Challenges

Quantifying Biased Agonism

Measuring G-protein versus β-arrestin recruitment remains inconsistent across assays. Kruegel et al. (2016) highlight variability in mitragynine signaling profiles at mu-opioid receptors. Standardization of biased agonism metrics is needed for derivative optimization.

Adrenergic Site Specificity

Mitragynine's alpha-2 adrenergic interactions complicate opioid selectivity profiles. Takayama (2004) reports binding at multiple sites, requiring dissection of contributions to analgesia. Selective modulators demand precise SAR elucidation.

Translational Pain Models

Mouse antinociception data (Matsumoto et al., 2004) poorly predict human efficacy due to species differences. Hassan et al. (2012) note behavioral effects vary with dose and context. Human-relevant models are essential for clinical advancement.

Essential Papers

From Kratom to mitragynine and its derivatives: Physiological and behavioural effects related to use, abuse, and addiction

Zurina Hassan, Muzaimi Mustapha, Visweswaran Navaratnam et al. · 2012 · Neuroscience & Biobehavioral Reviews · 372 citations

Chemistry and Pharmacology of Analgesic Indole Alkaloids from the Rubiaceous Plant, Mitragyna speciosa

Hiromitsu Takayama · 2004 · Chemical and Pharmaceutical Bulletin · 344 citations

The leaves of a tropical plant, Mitragyna speciosa KORTH (Rubiaceae), have been traditionally used as a substitute for opium. Phytochemical studies of the constituents of the plant growing in Thail...

Self‐treatment of opioid withdrawal using kratom (<i>Mitragynia speciosa korth</i>)

Edward W. Boyer, Kavita M. Babu, Jessica E. Adkins et al. · 2008 · Addiction · 339 citations

ABSTRACT Background Kratom ( Mitragynia speciosa korth ) is recognized increasingly as a remedy for opioid withdrawal by individuals who self‐treat chronic pain. Case description A patient who had ...

Synthetic and Receptor Signaling Explorations of the <i>Mitragyna</i> Alkaloids: Mitragynine as an Atypical Molecular Framework for Opioid Receptor Modulators

Andrew C. Kruegel, Madalee M. Gassaway, Abhijeet Kapoor et al. · 2016 · Journal of the American Chemical Society · 296 citations

Mu-opioid receptor agonists represent mainstays of pain management. However, the therapeutic use of these agents is associated with serious side effects, including potentially lethal respiratory de...

Mitragynine/Corynantheidine Pseudoindoxyls As Opioid Analgesics with Mu Agonism and Delta Antagonism, Which Do Not Recruit β-Arrestin-2

András Váradi, Gina F. Marrone, Travis C. Palmer et al. · 2016 · Journal of Medicinal Chemistry · 295 citations

Natural products found in Mitragyna speciosa, commonly known as kratom, represent diverse scaffolds (indole, indolenine, and spiro pseudoindoxyl) with opioid activity, providing opportunities to be...

Studies on the Synthesis and Opioid Agonistic Activities of Mitragynine-Related Indole Alkaloids: Discovery of Opioid Agonists Structurally Different from Other Opioid Ligands

Hiromitsu Takayama, Hayato Ishikawa, Mika Kurihara et al. · 2002 · Journal of Medicinal Chemistry · 262 citations

Mitragynine (1) is a major alkaloidal component in the Thai traditional medicinal herb, Mitragyna speciosa, and has been proven to exhibit analgesic activity mediated by opioid receptors. By utiliz...

Antinociceptive effect of 7-hydroxymitragynine in mice: Discovery of an orally active opioid analgesic from the Thai medicinal herb Mitragyna speciosa

Kenjiro Matsumoto, Syunji Horie, Hayato Ishikawa et al. · 2004 · Life Sciences · 223 citations

Reading Guide

Foundational Papers

Start with Takayama (2004, 344 citations) for alkaloid isolation and pharmacology overview; Takayama et al. (2002, 262 citations) for synthesis and opioid activities; Hassan et al. (2012, 372 citations) for behavioral effects summary.

Recent Advances

Kruegel et al. (2016, 296 citations) on atypical opioid frameworks; Váradi et al. (2016, 295 citations) on pseudoindoxyls without β-arrestin-2 recruitment.

Core Methods

Radioligand binding for affinities; G-protein and β-arrestin assays for bias; synthesis of derivatives like 7-hydroxymitragynine for SAR (Takayama et al., 2002; Kruegel et al., 2016).

How PapersFlow Helps You Research Mitragynine Pharmacology and Receptor Interactions

Discover & Search

Research Agent uses searchPapers and citationGraph to map 372-citation Hassan et al. (2012) review to downstream works like Kruegel et al. (2016), revealing biased agonism clusters. exaSearch uncovers niche adrenergic binding studies; findSimilarPapers extends Takayama (2004) to 50+ SAR papers.

Analyze & Verify

Analysis Agent applies readPaperContent to extract binding affinities from Kruegel et al. (2016), then verifyResponse with CoVe checks claims against Váradi et al. (2016). runPythonAnalysis plots dose-response curves from Matsumoto et al. (2004) data using matplotlib; GRADE assigns A-grade to high-citation opioid signaling evidence.

Synthesize & Write

Synthesis Agent detects gaps in β-arrestin recruitment studies via contradiction flagging across Takayama (2002) and Váradi (2016). Writing Agent uses latexEditText for SAR tables, latexSyncCitations for 10-paper bibliographies, and latexCompile for receptor diagram PDFs; exportMermaid visualizes signaling pathways.

Use Cases

"Extract dose-response data from mitragynine mouse antinociception studies and plot IC50 curves."

Research Agent → searchPapers('mitragynine antinociception Matsumoto') → Analysis Agent → readPaperContent(Matsumoto 2004) → runPythonAnalysis(pandas curve fitting, matplotlib plots) → CSV export of fitted parameters and graphs.

"Draft LaTeX review section on mitragynine mu-opioid biased agonism with citations."

Synthesis Agent → gap detection(Kruegel 2016 + Váradi 2016) → Writing Agent → latexEditText(structured paragraph) → latexSyncCitations(15 papers) → latexCompile(PDF) → researcher gets formatted section with inline citations and figures.

"Find GitHub repos analyzing mitragynine receptor binding simulations."

Research Agent → searchPapers('mitragynine docking simulation') → paperExtractUrls → paperFindGithubRepo → githubRepoInspect(code, data) → researcher gets molecular dynamics scripts and docking datasets linked to Kruegel et al. (2016).

Automated Workflows

Deep Research workflow scans 50+ papers from Takayama (2004) citations, generating structured reports on receptor affinities with GRADE scores. DeepScan's 7-step chain verifies biased agonism claims: searchPapers → readPaperContent → runPythonAnalysis(EC50 stats) → CoVe. Theorizer hypothesizes novel pseudoindoxyl designs from Váradi (2016) SAR gaps.

Try Doxa for Mitragynine Pharmacology and Receptor Interactions Research

Frequently Asked Questions

What defines mitragynine pharmacology?

Mitragynine pharmacology studies its partial mu-opioid agonism, adrenergic binding, and biased signaling from Mitragyna speciosa (Takayama, 2004).

What are key methods for receptor studies?

Radioligand binding assays quantify mu-opioid affinities; β-arrestin recruitment assays profile bias (Kruegel et al., 2016). Mouse hot-plate tests measure antinociception (Matsumoto et al., 2004).

What are foundational papers?

Takayama (2004, 344 citations) details indole alkaloid pharmacology; Takayama et al. (2002, 262 citations) synthesizes opioid agonists; Hassan et al. (2012, 372 citations) reviews effects.

What open problems exist?

Standardizing biased agonism quantification across models; developing human-translatable pain assays; isolating adrenergic contributions from opioid effects (Kruegel et al., 2016).